Zydus Lifesciences Share Price (ZYDUSLIFE)
Check the latest share price of Zydus Lifesciences, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 13 Jun 2025
NSE
Zydus Lifesciences Stock Performance
Get live Zydus Lifesciences share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹960Day's Price Range₹977.752 Week's Low
52 Week's High
₹79552-Week Price Range₹1,324.3
| Returns % | |
| 1 Month Return | + 7.91 % |
| 3 Month Return | + 9.21 % |
| 1 Year Return | -12.13 % |
| 3 Year Return | + 177.13 % |
| 5 Year Return | + 162.9 % |
| Market Stats | |
| Previous Close | ₹978.80 |
| Open | ₹968.10 |
| Volume | 10.46L |
| Upper Circuit | ₹1,076.65 |
| Lower Circuit | ₹880.95 |
Zydus Lifesciences Fundamentals & Key Indicators
Check Zydus Lifesciences market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹98,102.78 Cr
Return on Equity (ROE)
23.45
PE Ratio (TTM)
21.68
Return on capital employed (ROCE)
22.73
Industry PE ratio
57.39
Beta (LTM)
0.76
P/B Ratio
6.43
Dividend Yield
0.3
PEG Ratio
3.17
Quarterly Earnings Growth YOY
1.61
EPS (TTM)
38.31
Sector
Pharmaceuticals
Book Value
197.11
Technical Analysis
Bullish
View Technical Analysis
How to invest in Zydus Lifesciences?
Investing in Zydus Lifesciences is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Zydus Lifesciences or ZYDUSLIFE on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Zydus Lifesciences or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Zydus Lifesciences with just a few clicks!
Zydus Lifesciences Stock's Interest Amongst Investors
Zydus Lifesciences Valuation
Track how Zydus Lifesciences P/E has moved over time to understand its valuation trends.
Zydus Lifesciences in the last 5 years
Lowest (7.34x)
March 7, 2022
Today (21.68x)
June 13, 2025
Industry (57.39x)
June 13, 2025
Highest (34.62x)
March 26, 2024
Today’s Price to Earnings Ratio: 21.68x
Zydus Lifesciences Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Zydus Lifesciences.
based on 32 analysts
43.75%
Buy
34.38%
Hold
21.88%
Sell
43.75% of analysts recommend a 'HOLD' rating for Zydus Lifesciences. Average target price of ₹986.5
Source: S&P Global Market Intelligence
Zydus Lifesciences Share Price Target
Get share price movements and forecasts by analysts on Zydus Lifesciences.
Zydus Lifesciences price forecast by 32 analysts
Upside of1.18%
High
₹1365
Target
₹986.50
Low
₹795
Zydus Lifesciences target price ₹986.5, a slight upside of 1.18% compared to current price of ₹974.95. According to 32 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Zydus Lifesciences revenue growth forecast
Expected growth rate Q1, FY2027:32.75%
Forecast
Actual
Including amortisation and stock based compensations
Zydus Lifesciences EPS growth forecast
EPS estimate Q1, FY2027:10.38%
Forecast
Actual
Source: S&P Global Market Intelligence
Zydus Lifesciences Financial Results
Get the annual and quarterly financial summary of Zydus Lifesciences, including revenue, profit, loss and more.
Indices Featuring Zydus Lifesciences Stock
Check stock indices that include Zydus Lifesciences.
Zydus Lifesciences Earnings and Dividends
View detailed summary of the earnings and dividend history of Zydus Lifesciences.
Zydus Lifesciences Ltd Earnings Results
Zydus Lifesciences Ltd’s net profit fell -0.96% since last year same period to ₹1,170.90Cr in the Q4 2024-2025. On a quarterly growth basis, Zydus Lifesciences Ltd has generated 14.4% jump in its net profits since last 3-months.
Read More about Earnings ResultsZydus Lifesciences Ltd Dividends May,2024
In the quarter ending March 2024, Zydus Lifesciences Ltd has declared dividend of ₹3 - translating a dividend yield of 0.92%.
Read More about Dividends
Zydus Lifesciences Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Zydus Lifesciences.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 74.99% | 0.00 | |
| Foreign Institutions | 7.32% | 0.00 | |
| Mutual Funds | 6.36% | 0.00 | |
| Retail Investors | 6.68% | 0.00 | |
| Others | 4.65% | 0.00 |
Zydus Lifesciences vs Peers
Compare market cap, revenue, PE, and other key metrics of Zydus Lifesciences with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| HOLD | 98,102.78 | 32.58% | 0.64 | 3,854 | 19,547 | |
| BUY | 14,157.69 | -4.54% | 0.52 | 413 | 2,013 | |
| BUY | 67,394.66 | 9.93% | 0.56 | 3,168 | 29,001 | |
| BUY | 66,969.38 | 19.17% | 0.53 | NA | NA | |
| BUY | 55,819.29 | 27.46% | 0.56 | 927 | 3,749 |
Zydus Lifesciences News & Key Events
Latest news and events in one place to help you make informed investing decisions in Zydus Lifesciences.
Zydus Lifesciences Gains After USFDA Inspection Approval - 12 Jun, 2025
Zydus Lifesciences shares increased by 1% following the receipt of the Establishment Inspection Report from the USFDA for its Ankleshwar facility, classified as No Action Indicated. The company also made a strategic entry into the global biologics CDMO market and received tentative approval for Rifaximin Tablets for IBS-D treatment.Zydus Lifesciences Receives Positive FDA Inspection Report - 11 Jun, 2025
Zydus Lifesciences announced receipt of the Establishment Inspection Report from the USFDA for its Ankleshwar API facility, classified as No Action Indicated, ensuring compliance and operational continuity.Zydus Lifesciences Receives USFDA EIR and Reports Earnings - 10 Jun, 2025
Zydus Lifesciences received the USFDA's Establishment Inspection Report for its Dabhasa facility, classified as VAI. The company reported a slight decline in Q4 FY25 net profit, while revenue increased significantly. Shares rose for the fifth consecutive session.Zydus Lifesciences Shows Strong Financial Outlook - 06 Jun, 2025
Zydus Lifesciences demonstrates strong financial performance with strategic acquisitions and R&D investments. Key metrics indicate a buy recommendation at ₹955, targeting ₹1,080 in three months.Zydus Lifesciences Expands Biologics and Patent Strategies - 05 Jun, 2025
Zydus Lifesciences is making significant moves by acquiring Agenus biologics facilities, reporting strong quarterly performance, and gaining favorable court rulings on patents. However, concerns about future US sales and margin pressures persist.Zydus Expands Biologics Footprint with Agenus Acquisitions - 03 Jun, 2025
Zydus Lifesciences is significantly enhancing its position in the global biologics market by acquiring two manufacturing facilities from Agenus and securing commercial rights for immuno-oncology therapies in India and Sri Lanka. The company also acquired a stake in Agenus, further solidifying its strategic focus on biologics as a growth driver.Zydus Lifesciences Secures USFDA Approval for Rifaximin - 02 Jun, 2025
Zydus Lifesciences has received tentative approval from the USFDA for Rifaximin Tablets, 550 mg, indicated for irritable bowel syndrome with diarrhea, with significant annual sales potential.Zydus Lifesciences Hits Two-Month High - 29 May, 2025
Zydus Lifesciences stock closed at a two-month high after breaking a falling trendline. The stock has shown repeated higher lows, indicating potential for further gains towards its 200 DMA near 980.Zydus Lifesciences Gains Fast Track for ALS Drug - 28 May, 2025
Zydus Lifesciences' stock reaches a two-month high following the USFDA's fast track designation for Usnoflast, a treatment for ALS, emphasizing the urgent need for effective therapies.Zydus Launches Impactful Breast Cancer Awareness Campaign - 27 May, 2025
Zydus Lifesciences has launched 'The Easiest Exam' campaign to promote self-breast examination for early breast cancer detection, reaching millions and gaining significant media attention.Zydus Receives FDA Approval for Acne Drug - 23 May, 2025
Zydus Lifesciences has received FDA approval for its isotretinoin capsules, a generic version of Absorica, for treating severe acne. This approval enhances Zydus's dermatological portfolio and reflects its commitment to expanding in key markets.Zydus Lifesciences Reports Strong Growth and Future Plans - 21 May, 2025
Zydus Lifesciences showcases strong Q4 results with a 34% net profit increase. The company plans to expand its vaccines and medtech portfolio, targeting double-digit growth in FY26. Analysts maintain a mix of ratings, with some optimistic about future performance despite concerns over margin pressures and product concentration.Zydus Lifesciences Reports Q4 Results and FY26 Outlook - 20 May, 2025
Zydus Lifesciences targets double-digit revenue growth for FY26, despite a dip in Q4 profit to ₹1,244 crore. The company declares a final dividend of ₹11 per share, pending AGM approval. Overall, strong performance in US and India markets supports growth outlook.Zydus Lifesciences Receives Favorable USFDA Inspection Report - 14 May, 2025
Zydus Lifesciences announced receipt of the Establishment Inspection Report (EIR) from USFDA for its Ambernath API manufacturing facility, with no observations and classified as No Action Indicated (NAI).
Insights on Zydus Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 6.32% to 6.36% in Mar 2025 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ZYDUSLIFE has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 5.30K Cr → 6.60K Cr (in ₹), with an average increase of 9.9% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 911.2 Cr → 1.17K Cr (in ₹), with an average increase of 11.8% per quarter
- POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 74.98% to 74.99% in Mar 2025 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 45.3% return, outperforming this stock by 57.4%
NEGATIVE IMPACTPrice Dip
In the last 6 months, ZYDUSLIFE stock has moved down by -1.3%
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 7.53% to 7.32% in Mar 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.84% to 6.68% in Mar 2025 quarter
About Zydus Lifesciences
The company has a strong presence in the global market and is known for its high-quality pharmaceutical products. It manufactures a wide range of generic and specialty drugs, including cardiovascular, anti-infective, anti-diabetic, and oncology medicines. Zydus also produces over-the-counter products and nutritional supplements. Some of its top products include Zetia, Atorvastatin, and Metformin.
Zydus Lifesciences Ltd is also known for its popular brands, such as Cadila, Nutralite, and Zydus Wellness. The company has a strong presence in the Indian market, with its products being sold in more than 20,000 stores across the country. It also exports its products to over 100 countries worldwide.
Revenue: ₹6,290.20Cr as on March 2025 (Q4 FY25)
Net Profit: ₹1,248.80Cr as on March 2025 (Q4 FY25)
Listing date: 18 Apr, 2000
Chairperson Name: Pankaj R Patel
| Organisation | Zydus Lifesciences Ltd |
| Headquarters | Ahmedabad |
| Industry | Pharmaceuticals |
| CEO | Pankaj R Patel |
| E-voting on shares | Click here to vote |
Mutual Funds that own Zydus Lifesciences
Check out the Mutual Funds with significant holdings in Zydus Lifesciences.
FAQs
What is Zydus Lifesciences share price today?
Zydus Lifesciences share price today stands at ₹974.95, Open: ₹968.1, Previous Close: ₹978.8, High: ₹977.7, Low: ₹960, 52 Week High: ₹1324.3, 52 Week Low: ₹795.
What is today's traded volume of Zydus Lifesciences?
Today's traded volume of Zydus Lifesciences is 10.46L. Which means that 10.46L shares of Zydus Lifesciences were bought and sold on the stock market during today's trading session.
What is Zydus Lifesciences's market cap today?
Today's market capitalisation of Zydus Lifesciences is ₹98,102.78 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Zydus Lifesciences?
Zydus Lifesciences’s 52 week high is ₹1324.3 and 52 week low is ₹795. The current share price of Zydus Lifesciences is ₹974.95, which is -26.38% down from its 52 week high and 22.64% up from its 52 week low.